Procalcitonin-Guided Antibiotic Therapy

Introduction to Procalcitonin Guidance

The American College of Critical Care Medicine recommends using procalcitonin (PCT) primarily to guide antibiotic discontinuation and duration rather than initiation decisions, with specific cutoffs of <0.5 µg/L in ICU patients or <0.25 µg/L in non-ICU patients supporting antibiotic cessation, or an 80% drop from peak levels—but never delay empiric antibiotics in suspected sepsis or high-risk patients while awaiting PCT results 1

The Society of Critical Care Medicine advises against withholding or delaying empiric antibiotics based on PCT levels in critically ill patients with suspected sepsis or septic shock, as immediate broad-spectrum antibiotics are mandatory regardless of PCT values 2, 1
The Infectious Diseases Society of America recommends not withholding or delaying empiric antibiotics in severely immunocompromised patients, as the risk of rapid deterioration outweighs concerns about antibiotic overuse 3, 1
The American Thoracic Society suggests that clinical assessment supersedes biomarker results in patients with high clinical probability of bacterial infection, and PCT should not be used to withhold antibiotics 4, 2

The Society of Critical Care Medicine recommends discontinuing antibiotics when PCT <0.5 µg/L or drops ≥80% from peak levels once ICU patients with sepsis clinically stabilize 2, 1
A 2023 meta-analysis of 16 studies showed PCT-guided discontinuation decreased antibiotic duration by 1 day and improved mortality, though evidence certainty was low 2

The American College of Critical Care Medicine notes that PCT has significant limitations, including sensitivity ranges of only 38-91% for bacterial infections, meaning low PCT cannot exclude infection 4, 2
The Infectious Diseases Society of America warns that non-infectious causes of PCT elevation, such as shock states, drug hypersensitivity reactions, and malignancies, can lead to misinterpretation of results 5

The Infectious Diseases Society of America recommends restrictive antibiotic use for mild-to-moderate COVID-19 based on stewardship principles, and PCT <0.25 ng/mL supports withholding antibiotics in less severe COVID-19 without clinical concern for bacterial co-infection 3, 6, 7, 8

The Society of Critical Care Medicine provides moderate certainty that PCT-guided discontinuation improves outcomes in ICU sepsis patients, based on the 2023 guidelines 2
The American Thoracic Society and Infectious Diseases Society of America explicitly state that PCT cannot justify withholding antibiotics in confirmed community-acquired pneumonia (CAP) 4

The primary role of PCT is to shorten antibiotic duration by 1-2 days when levels fall below 0.5 μg/L in ICU patients or decrease ≥80% from peak, not to intensify therapy when levels remain elevated, as recommended by the Infectious Diseases Society of America 9, 10

In ICU patients with sepsis who have clinically stabilized, discontinue antibiotics when PCT <0.5 μg/L or drops ≥80% from peak levels, according to the American College of Chest Physicians 9, 10
In non-ICU patients with respiratory infections, use PCT <0.25 ng/mL to support early discontinuation or withholding antibiotics in low-risk presentations, as suggested by the European Respiratory Society 11

A meta-analysis of ICU patients with severe sepsis showed median 2-day reduction in antibiotic therapy with PCT guidance, without negative effects on mortality, with a moderate strength of evidence 9, 10

Do not use PCT to justify adding empiric antifungals—fungal markers (beta-D-glucan, galactomannan) are more appropriate for this decision, as recommended by the Infectious Diseases Society of America 9, 10